Signs of hemodynamic instability (i.e. systolic blood pressure <100 mm Hg.St. or episode of systolic blood pressure fall for =40 mm Hg. / or heart rate > 110 lasting more than 15 min) or need for ventilatory support within 12 hours prior to randomisation.
The indication for oral anticoagulation, associated with others disease.
malignant neoplasm of any location
Contraindications to warfarin or pradaxa according to Russian Instructions for medical use of these drugs
Indications for concomitant treatment with antiplatelet agents
Any stroke within 6 months before randomization
Intracranial hemorrhage in anamnesis
Active bleeding, bleeding diathesis.
Clinically significant bleeding within the last 30 days.
Trauma or extensive surgery within 1 month before randomization or surgery planned in the next 6 months after randomization.
Intracranial pathology: tumor, arteriovenous fistula or aneurysm.
Gastrointestinal bleeding in the previous 3 months.
Gastric ulcer or duodenal ulcer with clinical manifestations or endoscopically identified acute ulcer without signs of scarring during previous 30 days.
Uncontrolled hypertension (systolic blood pressure> 180 mm Hg. and / or diastolic blood pressure> 100 mm.hg in patients receiving antihypertensive drugs).
Pregnancy, lactation.
Life expectancy <6 months.
Clinically significant liver disease.
Creatinine clearance (estimated by Cockcroft-Gault) <30 ml / min.
hemoglobin level <90 g/l), thrombocytopenia <100x10^9 / L.
Patients who, in the opinion of the researcher, are not suitable for inclusion in the study, for example, due to the low likelihood of doctor's recommendations following.
Long-term use of NSAIDs
Current participation in another clinical study.
Allergic to contrast substance or radioisotope drugs used in procedures to assess endpoints of the study, which according to researchers, may be a contraindication to the implementation of these research methods.

NCT02979561_exc_T1
Condition
hemodynamic instability
NCT02979561_exc_T2
Measurement
systolic blood pressure
NCT02979561_exc_T3
Value
<100 mm Hg.St.
NCT02979561_exc_T4
Measurement
systolic blood pressure fall
NCT02979561_exc_T5
Value
=40 mm Hg
NCT02979561_exc_T6
Measurement
heart rate
NCT02979561_exc_T7
Value
> 110
NCT02979561_exc_T8
Multiplier
lasting more than 15 min
NCT02979561_exc_T9
Procedure
ventilatory support
NCT02979561_exc_T10
Mood
need for
NCT02979561_exc_T11
Temporal
within 12 hours prior to randomisation
NCT02979561_exc_T12
Scope
systolic blood pressure <100 mm Hg.St. or episode of systolic blood pressure fall for =40 mm Hg. / or heart rate > 110 lasting more than 15 min
NCT02979561_exc_T13
Procedure
oral anticoagulation
NCT02979561_exc_T14
Mood
indication for
NCT02979561_exc_T15
Qualifier
malignant
NCT02979561_exc_T16
Condition
neoplasm
NCT02979561_exc_T17
Condition
Contraindications
NCT02979561_exc_T18
Drug
warfarin
NCT02979561_exc_T19
Drug
pradaxa
NCT02979561_exc_T20
Scope
warfarin or pradaxa
NCT02979561_exc_T21
Qualifier
Russian Instructions for medical use
NCT02979561_exc_T22
Drug
antiplatelet agents
NCT02979561_exc_T23
Temporal
concomitant
NCT02979561_exc_T24
Mood
Indications
NCT02979561_exc_T25
Condition
stroke
NCT02979561_exc_T26
Temporal
within 6 months before randomization
NCT02979561_exc_T27
Condition
Intracranial hemorrhage
NCT02979561_exc_T28
Procedure
anamnesis
NCT02979561_exc_T29
Condition
bleeding
NCT02979561_exc_T30
Condition
bleeding diathesis
NCT02979561_exc_T31
Qualifier
Clinically significant
NCT02979561_exc_T32
Condition
bleeding
NCT02979561_exc_T33
Temporal
within the last 30 days
NCT02979561_exc_T34
Condition
Trauma
NCT02979561_exc_T35
Procedure
extensive surgery
NCT02979561_exc_T36
Temporal
within 1 month before randomization
NCT02979561_exc_T37
Scope
Trauma or extensive surgery
NCT02979561_exc_T38
Procedure
surgery
NCT02979561_exc_T39
Mood
planned
NCT02979561_exc_T40
Temporal
in the next 6 months after randomization
NCT02979561_exc_T41
Condition
Intracranial pathology
NCT02979561_exc_T42
Condition
tumor
NCT02979561_exc_T43
Condition
arteriovenous fistula
NCT02979561_exc_T44
Condition
aneurysm
NCT02979561_exc_T45
Scope
tumor, arteriovenous fistula or aneurysm
NCT02979561_exc_T46
Condition
Gastrointestinal bleeding
NCT02979561_exc_T47
Temporal
in the previous 3 months
NCT02979561_exc_T48
Condition
Gastric ulcer
NCT02979561_exc_T49
Condition
duodenal ulcer
NCT02979561_exc_T50
Condition
clinical manifestations
NCT02979561_exc_T51
Qualifier
endoscopically identified
NCT02979561_exc_T52
Procedure
endoscopically
NCT02979561_exc_T53
Condition
acute ulcer
NCT02979561_exc_T54
Negation
without
NCT02979561_exc_T55
Condition
signs of scarring
NCT02979561_exc_T56
Temporal
during previous 30 days
NCT02979561_exc_T57
Qualifier
Uncontrolled
NCT02979561_exc_T58
Condition
hypertension
NCT02979561_exc_T59
Measurement
systolic blood pressure
NCT02979561_exc_T60
Value
> 180 mm Hg
NCT02979561_exc_T61
Measurement
diastolic blood pressure
NCT02979561_exc_T62
Value
> 100 mm.hg
NCT02979561_exc_T63
Drug
antihypertensive drugs
NCT02979561_exc_T64
Scope
systolic blood pressure> 180 mm Hg. and / or diastolic blood pressure> 100 mm.hg in patients receiving antihypertensive drugs
NCT02979561_exc_T65
Condition
Pregnancy
NCT02979561_exc_T66
Condition
lactation
NCT02979561_exc_T67
Observation
Life expectancy
NCT02979561_exc_T68
Value
<6 months
NCT02979561_exc_T69
Qualifier
Clinically significant
NCT02979561_exc_T70
Condition
liver disease
NCT02979561_exc_T71
Measurement
Creatinine clearance
NCT02979561_exc_T72
Qualifier
Cockcroft-Gault
NCT02979561_exc_T73
Value
<30 ml / min
NCT02979561_exc_T74
Measurement
hemoglobin level
NCT02979561_exc_T75
Value
<90 g/l
NCT02979561_exc_T76
Condition
thrombocytopenia
NCT02979561_exc_T77
Value
<100x10^9 / L
NCT02979561_exc_T79
Drug
NSAIDs
NCT02979561_exc_T80
Multiplier
Long-term use
NCT02979561_exc_T82
Condition
Allergic
NCT02979561_exc_T83
Drug
contrast substance
NCT02979561_exc_T84
Drug
radioisotope drugs
NCT02979561_exc_T85
Scope
contrast substance or radioisotope drugs
NCT02979561_exc_T86
Qualifier
Active